NSE filing, NSE: SHALBY. Summary written from the filing by ALFA Finder's alert engine.
Shalby Ltd: key numbers
- Share price
- ₹122.01
- Market cap
- ₹1,318 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 33.6×Sector 53.8×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Earnings Call Transcript: Key Takeaways
Consolidated revenue rose 9.8%, but EBITDA grew only 0.8% and margin fell 130 bps to 14.6%. PAT was flat at ₹7.9 Cr. Standalone hospitals carry profit while subsidiaries drag. Management deflected on Mumbai, MedTech expansion and POSO revenue.
Shalby Investor Presentation: Key Takeaways
Consolidated Q2 FY27 revenue ₹3,182mn (+9.8% YoY), EBITDA flat at ₹464mn, margin 14.6%, PAT ₹79mn (+8.3%). Standalone PAT +19%; growth driven by International and occupancy.
Shalby Annual General Meeting
Shalby Ltd seeks shareholder approval via postal ballot to appoint Shanay Vikram Shah and Tushar Shah as directors. E-voting runs November 5 to December 4, 2026.
Shalby Management Change
Shalby Limited appointed Mr. Tushar Shah as Executive Director for five years, effective November 3, 2026, subject to shareholder approval. The change is a senior management appointment.
- Execution
- 5 years from November 3, 2026
Shalby Q2 FY27 Results: Net Profit ₹7.9 Cr, Up 8.2% YoY
Shalby Ltd reported revenue from operations of ₹313.2 Cr (+9.7% YoY) and net profit of ₹7.9 Cr (+8.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.9 Cr · +8.2% YoY
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Other other announcement announcements
All →Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.
Physicswallah Other Announcement
Physicswallah's IPO monitoring report flags a deviation from offer objects for the quarter ended September 30, 2026. The diverted funds were restored on October 30, 2026.
Gujarat Kidney and Super Speciality Other Announcement
Gujarat Kidney filed Brickwork's monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation from the IPO fund-utilisation objects.
PDS Other Announcement
PDS Limited submitted the CRISIL Ratings monitoring agency report for the quarter ended September 30, 2026. It confirms no deviation in the utilisation of its QIP proceeds.
Schaeffler India Other Announcement
Schaeffler India disclosed that CRISIL ESG Ratings assigned it an ESG Score of 67 on an unsolicited basis. The company did not engage or subscribe to the rating provider.